Marco H. Hofmann

2.2k total citations · 1 hit paper
41 papers, 953 citations indexed

About

Marco H. Hofmann is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Marco H. Hofmann has authored 41 papers receiving a total of 953 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Hematology. Recurrent topics in Marco H. Hofmann's work include Growth Hormone and Insulin-like Growth Factors (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer-related Molecular Pathways (6 papers). Marco H. Hofmann is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (8 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer-related Molecular Pathways (6 papers). Marco H. Hofmann collaborates with scholars based in Austria, Germany and United States. Marco H. Hofmann's co-authors include Ulrich M. Zanger, Matthias Schwab, Kathrin Klein, Tanja Saußele, Julia Blievernicht, Elke Schaeffeler, Norbert Kraut, Michael Gmachl, Günther R. Adolf and Kenichi Suda and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Marco H. Hofmann

36 papers receiving 940 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marco H. Hofmann Austria	13	489	301	229	129	123	41	953
Araba A. Adjei United States	19	616 1.3×	377 1.3×	209 0.9×	145 1.1×	214 1.7×	32	1.3k
Ina Koch Germany	18	505 1.0×	689 2.3×	621 2.7×	143 1.1×	215 1.7×	33	1.6k
Emiko Sugiyama Japan	15	257 0.5×	395 1.3×	210 0.9×	121 0.9×	125 1.0×	32	1.0k
Nicola F. Smith United States	16	618 1.3×	605 2.0×	243 1.1×	56 0.4×	74 0.6×	22	1.3k
Yuzhuo Pan United States	13	348 0.7×	260 0.9×	153 0.7×	181 1.4×	161 1.3×	27	845
Suman Lal Singapore	14	186 0.4×	264 0.9×	157 0.7×	48 0.4×	58 0.5×	26	859
Mohamed Elmeliegy United States	16	304 0.6×	583 1.9×	86 0.4×	80 0.6×	289 2.3×	52	944
Zhengyu Xue United States	12	236 0.5×	169 0.6×	130 0.6×	79 0.6×	176 1.4×	18	603
Haijian Wang China	17	588 1.2×	286 1.0×	153 0.7×	206 1.6×	104 0.8×	43	1.0k
Nathalie Gérard France	21	304 0.6×	219 0.7×	337 1.5×	59 0.5×	42 0.3×	58	1.3k

Countries citing papers authored by Marco H. Hofmann

Since Specialization

Citations

This map shows the geographic impact of Marco H. Hofmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco H. Hofmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco H. Hofmann more than expected).

Fields of papers citing papers by Marco H. Hofmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco H. Hofmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco H. Hofmann. The network helps show where Marco H. Hofmann may publish in the future.

Co-authorship network of co-authors of Marco H. Hofmann

This figure shows the co-authorship network connecting the top 25 collaborators of Marco H. Hofmann. A scholar is included among the top collaborators of Marco H. Hofmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco H. Hofmann. Marco H. Hofmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baltanás, Fernando C., Rósula García‐Navas, Enrico Patrucco, et al.. (2025). SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS ^G12D inhibitor in KRAS LUAD. Proceedings of the National Academy of Sciences. 122(11). e2422943122–e2422943122. 1 indexed citations

Hofmann, Marco H., Kaja Kostyrko, Robyn L. Schenk, et al.. (2025). SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR -mutant lung cancer. Science Signaling. 18(914). eaea2788–eaea2788. 1 indexed citations

Moser, Othmar, et al.. (2025). Head-to-Head Comparison of Two Automated Insulin Delivery Systems in Children with Type 1 Diabetes during a 2-Week Summer Camp: An Exploratory Prospective Study. Hormone Research in Paediatrics. 1–9.

Hofmann, Marco H., et al.. (2024). FASTMAP—a flexible and scalable immunopeptidomics pipeline for HLA- and antigen-specific T-cell epitope mapping based on artificial antigen-presenting cells. Frontiers in Immunology. 15. 1386160–1386160. 2 indexed citations

Hofmann, Irmgard, Anke Baum, Marco H. Hofmann, et al.. (2022). Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition. Journal of Pharmacology and Experimental Therapeutics. 384(3). 331–342. 9 indexed citations

Hofmann, Marco H., Hengyu Lu, Daniel Gerlach, et al.. (2021). Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.. Cancer Research. 81(13_Supplement). CT210–CT210. 13 indexed citations

Koga, T., Kenichi Suda, Toshio Fujino, et al.. (2021). KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. Journal of Thoracic Oncology. 16(8). 1321–1332. 167 indexed citations breakdown →

Weyer-Czernilofsky, Ulrike, Marco H. Hofmann, Katrin Friedbichler, et al.. (2020). Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Molecular Cancer Therapeutics. 19(4). 1059–1069. 14 indexed citations

Jankowski, Wojciech, Yara Park, Joseph R. McGill, et al.. (2019). Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. Blood Advances. 3(9). 1429–1440. 20 indexed citations

10.

Sanderson, Michael P., Marco H. Hofmann, Pilar Garin‐Chesa, et al.. (2017). The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy. Molecular Cancer Therapeutics. 16(10). 2223–2233. 22 indexed citations

11.

Schaaf, Otmar, Marco H. Hofmann, Michael P. Sanderson, et al.. (2017). An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor. Cancer Chemotherapy and Pharmacology. 79(3). 545–558. 6 indexed citations

12.

Schaaf, Otmar, Marco H. Hofmann, Michael P. Sanderson, et al.. (2016). A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques. Cancer Chemotherapy and Pharmacology. 77(6). 1303–1314. 5 indexed citations

13.

Tontsch-Grunt, Ulrike, Fabio Savarese, Anke Baum, et al.. (2016). Effects of the novel BET inhibitor BI 894999 on upregulation of HEXIM1 in cancer cells and on antitumor activity in xenograft tumor models.. Journal of Clinical Oncology. 34(15_suppl). 11574–11574. 1 indexed citations

14.

Sanderson, Michael P., Joshua F. Apgar, Pilar Garin‐Chesa, et al.. (2015). BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis. Molecular Cancer Therapeutics. 14(12). 2762–2772. 16 indexed citations

15.

Friedbichler, Katrin, Marco H. Hofmann, Elínborg Ostermann, et al.. (2013). Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin. Molecular Cancer Therapeutics. 13(2). 399–409. 73 indexed citations

16.

Tennagels, Norbert, et al.. (2013). Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats. Diabetologia. 56(8). 1826–1834. 13 indexed citations

17.

Adam, Paul J., Katrin Friedbichler, Marco H. Hofmann, et al.. (2012). BI 836845, a fully human IGF ligand neutralizing antibody, to improve the efficacy of rapamycin by blocking rapamycin-induced AKT activation.. Journal of Clinical Oncology. 30(15_suppl). 3092–3092. 4 indexed citations

18.

Giesemann, Torsten, Julia Schueler, Vincent Vuaroqueaux, et al.. (2010). 634 Patient-derived breast cancer xenografts: Molecular characteristics and growth properties. European Journal of Cancer Supplements. 8(7). 198–199. 1 indexed citations

19.

Hofmann, Marco H., et al.. (2009). A Short Hairpin DNA Analogous to miR-125b Inhibits C-Raf Expression, Proliferation, and Survival of Breast Cancer Cells. Molecular Cancer Research. 7(10). 1635–1644. 42 indexed citations

20.

Zanger, Ulrich M., Kathrin Klein, Tanja Saußele, et al.. (2007). PolymorphicCYP2B6: Molecular Mechanisms and Emerging Clinical Significance. Pharmacogenomics. 8(7). 743–759. 196 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact